GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.
Rong D, Wang Y, Liu L, Cao H, Huang T, Liu H, Hao X, Sun G, Sun G, Zheng Z, Kang J, Xia Y, Chen Z, Tang W, Wang X.
Rong D, et al. Among authors: tang w.
J Immunother Cancer. 2023 Feb;11(2):e005126. doi: 10.1136/jitc-2022-005126.
J Immunother Cancer. 2023.
PMID: 36787938
Free PMC article.